Madhya Pradesh Online Journal

Non-small cell lung cancer Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies – Novartis Pharmaceuticals, AbbVie, Xcovery, Sanofi, Takeda Pharmaceuticals, Merck KGaA

 Breaking News
  • No posts were found

Non-small cell lung cancer Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies – Novartis Pharmaceuticals, AbbVie, Xcovery, Sanofi, Takeda Pharmaceuticals, Merck KGaA

November 29
19:42 2022
Non-small cell lung cancer Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - Novartis Pharmaceuticals, AbbVie, Xcovery, Sanofi, Takeda Pharmaceuticals, Merck KGaA
The Non-small cell lung cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-small cell lung cancer pipeline products will significantly revolutionize the Non-small cell lung cancer market dynamics.

DelveInsight’s “Non-small cell lung cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Non-small cell lung cancer, historical and forecasted epidemiology as well as the Non-small cell lung cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Non-small cell lung cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Non-small cell lung cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-small cell lung cancer Market Insights

 

Non-small cell lung cancer Overview

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and accounted for approximately 85% of all lung cancers. However, NSCLC metastasis to other organs is slower in comparison to SCLC, and microscopically, SCLC is composed of much smaller cells. NSCLC is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas.

 

Some of the key facts of the Non-small cell lung cancer Market Report: 

  • The Non-small cell lung cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • The United States had 227,875 incident cases of Lung Cancer in 2020, of which ~85%, i.e., 193,694 were NSCLC cancer patients
  • According to estimates, the United States has the highest incidence of EGFR-NSCLC, accounting for around 34% of the overall population with EGFR-mutated NSCLC in the 7MM (in 2020)
  • Key Non-small cell lung cancer Companies: Novartis Pharmaceuticals, AbbVie, Xcovery, Sanofi, Takeda Pharmaceuticals, Merck KGaA, Pfizer, Mirati Therapeutics, Incyte Corporation, Amgen, Phosplatin Therapeutics, Onconova, NeoImmuneTech, and others
  • Key Non-small cell lung cancer Therapies: Nazartinib/EGF816, Telisotuzumab Vedotin, Ensartinib/X-396, SAR4087012, Braftovi + Mektovi, TAK-788, Canakinumab (ACZ885), Avelumab (Bavencio), Veliparib, Sitravatinib, INCMGA00012, MGA012, Romiplostim, PT-112, Rigosertib, NT-I7, and others

 

Get a Free sample for the Non-small cell lung cancer Market Report 

https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-market

 

Key benefits of the Non-small cell lung cancer Market report:

  1. Non-small cell lung cancer market report covers a descriptive overview and comprehensive insight of the Non-small cell lung cancer Epidemiology and Non-small cell lung cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Non-small cell lung cancer market report provides insights on the current and emerging therapies.
  3. Non-small cell lung cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Non-small cell lung cancer market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Non-small cell lung cancer market.

 

Download the report to understand which factors are driving Non-small cell lung cancer epidemiology trends @ Non-small cell lung cancer Epidemiological Insights 

 

Non-small cell lung cancer Market  

The dynamics of the Non-small cell lung cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.  

 

Non-small cell lung cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Non-small cell lung cancer Epidemiology Segmentation:

The Non-small cell lung cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Non-small cell lung cancer
  • Prevalent Cases of Non-small cell lung cancer by severity
  • Gender-specific Prevalence of Non-small cell lung cancer
  • Diagnosed Cases of Episodic and Chronic Non-small cell lung cancer

 

Non-small cell lung cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-small cell lung cancer market or expected to get launched during the study period. The analysis covers Non-small cell lung cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Non-small cell lung cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Non-small cell lung cancer market share @ Non-small cell lung cancer market forecast 

 

Non-small cell lung cancer Therapies and Key Companies

  • Nazartinib/EGF816: Novartis Pharmaceuticals
  • Telisotuzumab Vedotin: AbbVie
  • Ensartinib/X-396: Xcovery
  • SAR4087012: Sanofi
  • Braftovi + Mektovi: Xcovery
  • TAK-788: Takeda Pharmaceuticals
  • Canakinumab (ACZ885): Novartis Pharmaceuticals
  • Avelumab (Bavencio): Merck KGaA and Pfizer
  • Veliparib: AbbVie
  • Sitravatinib: Mirati Therapeutics
  • INCMGA00012/MGA012: Incyte Corporation
  • Romiplostim: Amgen
  • PT-112: Phosplatin Therapeutics
  • Rigosertib: Onconova
  • NT-I7: NeoImmuneTech

 

Scope of the Non-small cell lung cancer Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Non-small cell lung cancer Companies: Novartis Pharmaceuticals, AbbVie, Xcovery, Sanofi, Takeda Pharmaceuticals, Merck KGaA and Pfizer, Mirati Therapeutics, Incyte Corporation, Amgen, Phosplatin Therapeutics, Onconova, NeoImmuneTech, and others
  • Key Non-small cell lung cancer Therapies: Nazartinib/EGF816, Telisotuzumab Vedotin, Ensartinib/X-396, SAR4087012, Braftovi + Mektovi, TAK-788, Canakinumab (ACZ885), Avelumab (Bavencio), Veliparib, Sitravatinib, INCMGA00012, MGA012, Romiplostim, PT-112, Rigosertib, NT-I7, and others
  • Non-small cell lung cancer Therapeutic Assessment: Non-small cell lung cancer current marketed and Non-small cell lung cancer emerging therapies
  • Non-small cell lung cancer Market Dynamics:  Non-small cell lung cancer market drivers and Non-small cell lung cancer market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Non-small cell lung cancer Unmet Needs, KOL’s views, Analyst’s views, Non-small cell lung cancer Market Access and Reimbursement 

 

Table of Contents 

1. Non-small cell lung cancer Market Report Introduction

2. Executive Summary for Non-small cell lung cancer

3. SWOT analysis of Non-small cell lung cancer

4. Non-small cell lung cancer Patient Share (%) Overview at a Glance

5. Non-small cell lung cancer Market Overview at a Glance

6. Non-small cell lung cancer Disease Background and Overview

7. Non-small cell lung cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Non-small cell lung cancer 

9. Non-small cell lung cancer Current Treatment and Medical Practices

10. Non-small cell lung cancer Unmet Needs

11. Non-small cell lung cancer Emerging Therapies

12. Non-small cell lung cancer Market Outlook

13. Country-Wise Non-small cell lung cancer Market Analysis (2019–2032)

14. Non-small cell lung cancer Market Access and Reimbursement of Therapies

15. Non-small cell lung cancer Market Drivers

16. Non-small cell lung cancer Market Barriers

17.  Non-small cell lung cancer Appendix

18. Non-small cell lung cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Non-small cell lung cancer treatment, visit @ Non-small cell lung cancer Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/